Backer will be responsible for all aspects of chemistry, manufacturing and controls (CMC) in support of Jennerex’s late-stage product, JX-594, as well as pipeline products.
Prior to join Jennerex, Backer worked as principal of Biologics Technical Consulting, where he provided strategic and technical consulting services supporting developers of biological products.
Jennerex president and CEO David H Kirn said that they are extremely pleased to welcome Mark to the executive management team, as he brings over 30 years of experience leading all aspects of operations in development-stage and commercial biopharmaceutical companies.
"His depth of expertise specifically in viral vaccine manufacturing and process development will be instrumental as we look forward to the initiation of our late stage clinical trials, and the development of our commercial manufacturing strategy for JX-594," Kirn said.